Eli Lilly (LLY +0.23%) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts, and analysts targeting $1,500, this healthcare powerhouse may still have substantial upside ahead for long-term investors.
Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 17, 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Prediction: Eli Lilly Stock Could Surge 45% This Year
Eli Lilly (LLY +0.23%) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts, and analysts targeting $1,500, this healthcare powerhouse may still have substantial upside ahead for long-term investors.
Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 17, 2026.